Kornimate/medical-research-clean huggingface dataset:
the study of skeletal muscle function in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purposes of this study includes (1)to investigate inspiratory muscles and non-inspiratory muscle function in terms of strength, endurance, and fatigability in patients with obstructive sleep apnea (osa), (2) investigate the metabolic characteristics of peripheral muscles and biochemistry markers in patients with osa, and (3) to detect the effect of exercise training on the measured parameters in patients with osa.

it has become increasingly recognized that skeletal muscle abnormalities are common and profound in patients with chronic inflammatory status. based on the unique character of obstructive sleep apnea (osa), repeated intermittent apnea and hypopnea caused by the upper airway muscles collapse during inspiration, it is logical to speculate some adaptations in skeletal muscle of patients with osa. the purpose of the first part is to investigate the inspiratory muscle function in patients with different severity of osa. participants firstly underwent polysomnography assessments will be recruited. the measurements includes epworth sleepiness scale, strength and endurance of inspiratory muscles, and fatigue test during either maximal voluntary efforts or in response to cervical magnetic stimulation (cms) with simultaneously semg recordings. in addition, the exercise capacity with simultaneous semg recordings for diaphragm and vastus lateralis during the exercise testing will also be tested. the second part is designed to examine the metabolic characteristics of lower extremity in patients with osa. blood samples will be drawn and proton magnetic resonance spectroscopy is used to detect intramyocellular and extramyocellular lipid contents (imcl and emcl). the third part will detect the effect of exercise training on the measured parameters described as above in patients with osa. participants will be randomized into exercise group, inspiratory muscle training group (imt), and cpap group. exercise protocol includes 30-minute aerobic exercise at the intensity of 70%-85% vo2max, and 20-minute general resistance exercise. imt group will receive inspiratory muscle strengthening by device.

Eligibility criteria:
inclusion criteria: * ages from 40-65 years men who first underwent polysomnography at the sleep research center. exclusion criteria: * subjects who had active medical or nervous system diseases, abnormal pulmonary function, morbid obesity, diabetes managed with oral hypoglycemic agents, alcoholism (≥ 50 gm per day), or a recent infection.

Keywords: obstructive sleep apnea skeletal muscle magnetic stimulation magnetic resonance spectroscopy inflammatory markers exercise
treatment approach in the multimodal era registry

Conditions: Chronic Thromboembolic Pulmonary Hypertension; CTEPH

Summary: the goal of this observational patient registry is to learn how expert centers treat patients with chronic thromboembolic pulmonary hypertension (cteph). cteph is a condition in which blood clots block the blood vessels in the lungs. there are currently three treatment options for patients with cteph: * surgery to remove blood clots from large vessels in the lungs (pulmonary endarterectomy (pea)) * the use of a small balloon to unblock smaller blood vessels (balloon pulmonary angioplasty (bpa)) * drugs patients can also receive a combination of these treatments. the main question this registry aims to answer are: * how many patients receive a given kind of treatment? * how do expert centers combine the different treatments? * are patients doing better after they receive a given kind of treatment? * how many patients are alive 1, 3 and 5 years after they receive a given kind of treatment? participants will receive the same treatments that they would receive if they did not participate in the study. during the study, patients will visit their doctors as they would do normally. the doctors will collect information on the patients' health and enter it into the study database. the follow-up time will be at least 3 years for all patients.


Eligibility criteria:
inclusion criteria: 1. newly referred patient with cteph or chronic thromboembolic pulmonary disease (ctepd) without ph according to the following criteria: 1. mean pulmonary arterial pressure (mpap) \> 20 mmhg at rest with pulmonary vascular resistance (pvr) \> 2 wood units (wu); or if mpap ≤ 20 mmhg or pvr ≤ 2 wu at rest, have exercise limitations from ctepd without ph 2. abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming ctepd as recommended by standard guidelines 2. treatment with anticoagulation for ≥ 3 months before diagnosis of cteph or ctepd without ph 3. naïve to interventional treatment (both pea and bpa) 4. pre-treatment with ph-specific medication for ≤ 12 months, or no medical pre-treatment, at enrollment 5. willing and able to provide informed consent in order to participate in the study (informed consent signed) 6. age ≥ 18 years 7. cteph-specific treatment must be modified or initiated at the participating site exclusion criteria: 1. main cause of ph other than cteph 2. participating in an interventional clinical trial at enrollment

Keywords: chronic thromboembolic pulmonary hypertension cteph pulmonary endarterectomy pea balloon pulmonary angioplasty bpa multimodal treatment
the influence of cortical bone perforation on guided bone regeneration in humans

Conditions: Alveolar Bone Loss

Summary: the purpose of this randomized clinical trial was to evaluate the effect of cortical bone decortication on the angiogenesis and osteogenesis of augmented ridge by gbr.

background: the purpose of the current study was to evaluate the effect of cortical bone perforation on angiogenesis and osteogenesis of augmented ridge by guided bone regeneration. methods: fourteen patients (mean age: 52) who were in need of dental implants at areas with osseous defects in the mandible were selected. in the test group (n=7), alveolar cortical bone at the area of regeneration was perforated using a #2 high speed round bur. no decortication of cortical bone was performed in the control group (n=7). subsequently, defects were augmented by guided bone regeneration using resorbable membrane and bovine bone. after a healing period of 7 months, implant sites were created and trephine cores harvested for histological and histomorphometric analysis of the grafted areas.

Eligibility criteria:
inclusion criteria: * inclusion criteria were presence of atrophic mandibular ridges with bucco-lingual width ranging between 2-5 mm, as measured on serial sections of a computerized axial tomography (cat) scan. exclusion criteria: * exclusion criteria included patients with diabetes, osteoporosis or other metabolic disorders, smokers, pregnant patients and patients who had any systemic or local factors that would inhibit normal wound healing process.

Keywords: histomorphometry
a dose finding study to assess the effect of lik066 compared to placebo or empagliflozin in patients with type 2 diabetes mellitus and heart failure

Conditions: Diabetes Mellitus and Heart Failure

Summary: this was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of lik066 compared to placebo or empagliflozin in t2dm patients with heart failure

the study was prematurely discontinued on 04-may-2018 due to slow enrollment that would preclude obtaining study results in a timely manner.

Eligibility criteria:
key inclusion criteria: * bmi ≥ 22kg/m\^2 * type 2 diabetes with hba1c between 6.5% and 10.0% * documented symptomatic chronic heart failure (nyha ii-iv) * plasma nt-probnp \> 300pg/ml * egfr ≥ 45ml/min/1.73m\^2 (calculated by mdrd) key exclusion criteria: * pregnant or nursing (lactating) women * type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes * history of ketoacidosis, lactic acidosis, or hyperosmolar coma * symptomatic genital infection or uti within 4 weeks of screening * myocardial infarction, stroke, surgery for heart disease, percutaneous coronary intervention within 3 months of randomization * unstable angina within 3 months of screening * isolated right hf due to pulmonary disease * patients with a mean sitting systolic blood pressure ≤ 100mmhg, at randomization * history of lower limb amputation * diabetic foot ulcer at screening

Keywords: diabetes mellitus lik066 obesity type 2 diabetes mellitus (t2dm) heart failure (hf) hypertension renal dysfunction adult-onset diabetes noninsulin-dependent diabetes mellitus (niddm) high blood sugar
comparison of ultrafast echo with echotracking

Conditions: Essential Untreated Hypertension; Healthy Volunteers

Summary: the aim is to compare a new technique for assessing mechanical properties of large arteries: the ultrafast echo with the reference technique, the echotracking. this will be done by studying in parallel hypertensive patients and controls with both techniques and this will revisit old concepts of increased stiffness in hypertensive arteries.

ultrafast echo is a new non invasive method for assessing stiffness of living tissues. it takes advantage of very fast imaging technologies (up to 20 000 images/sec) to measure the diffusion of pressure waves in the tissues. this pressure wave can be either natural (blood pressure), or generated by an very short ultrasonic impulsion at a given place. by using both modes, it is possible to have a precise cartography of tissue mechanical properties. this technique is applied to solid tissues such as breast or liver, but not yet currently to hollow tissues such as arteries. the aim of the present study is to compare the values of stiffness obtained with ultrafast echo with the reference non invasive technique, the echotracking, which measures stiffness by assessing the deformation of arteries in response to changes in blood pressure. on the physiological part, we will revisit old concepts of increased stiffness of hypertensive's arteries. indeed, hypertension is associated with increased stiffness due to recruitement of collagen fibers, but also to chronic remodelling. we have shown before that this remodelling conducts to accumulation of arterial tissue of lesser intrinsic stiffness. the latter finding was done through models based on echotracking measurements. it will be interesting to see whether it holds true when stiffness is directly measured. sixty subjects (30 normotensive and30 hypertensives) will be included and studied once. measurement will be performed in random order 3 time on the common carotid artery on both sides. aortic stiffness will be measured by pulse wave velocity

Eligibility criteria:
inclusion criteria: * hypertension, * essential (who workup), * untreated (\> 28 days of treatment interruption, \ 140 and/or 90 mmhg) exclusion criteria: * any concomitant severe disease compromising patient's participation or compliance

Keywords: large arteries stiffness intima media thickness ultrasound imaging
effect of intermittent and continuous theta burst stimulation on sleep, daytime sleepiness, and fatigue in depression

Conditions: Unipolar Depression; Bipolar Disorder

Summary: intermittent and continuous theta-burst stimulation (itbs and ctbs respectively) are the newer modalities of transcranial magnetic stimulation with documented efficacy in treatment of depressed mood but with conflicting results regarding their efficacy in treatment of other symptoms of depression such as insomnia, daytime sleepiness and fatigue. this study will investigate the efficacy of itbs over the left dorsolateral prefrontal cortex (dlpfc) and ctbs over the right dlpfc, compared to sham stimulation, in treatment of insomnia, daytime sleepiness and fatigue in depression.

intermittent and continuous theta-burst stimulation (itbs and ctbs respectively) are the newer modalities of conventional repetitive transcranial magnetic stimulation (rtms) with documented noninferiority in improving mood in depressive disorders. the effect of both modalities on other significant depression symptoms has not been studied. in this feasibility study investigators aim primarily to assess the safety and therapeutic potential of itbs over the left dorsolateral prefrontal cortex (ldlpfc) and ctbs over the right dorsolateral prefrontal cortex (rdlpfc) on sleep quality, sleep propensity, fatigue, and daytime sleepiness in patients with major and bipolar depression.

Eligibility criteria:
inclusion criteria: * severe or moderate depressive episode (according to international classification of diseases (icd)-10) without psychotic symptoms at the time of inclusion * diagnosis of major depression (f33.1 or f33.2) or bipolar disorder (f31.3 or f31.4). * the score of the athens insomnia scale five or more * unchanged antidepressive pharmacotherapy at least one month prior to inclusion exclusion criteria: * contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy * psychotic symptoms at the time of inclusion * suicidal ideations and/or attempts within three months prior to inclusion

Keywords: unipolar depression bipolar disorder theta burst stimulation sleep sleepiness fatigue transcranial magnetic stimulation
thalassemic iron overload cardiomyopathy is ameliorated by taurine supplementation

Conditions: Thalassemia Major

Summary: hypothesis: taurine, in combination with standard iron chelation therapy, is more effective than chelation therapy alone in reducing cardiac iron overload, oxidative stress and cardiac damage in β-thalassemia. protocol: sixty subjects with transfusion dependent β-thalassemia receiving deferasirox iron chelation therapy will be recruited and randomized in a 1:1 ratio to either (1) placebo and continuation of their iron chelation or (2) a combination of iron chelation plus taurine. transfusion and safety visits will be scheduled monthly with clinical/biochemical assessment visits every three months. the efficacy of taurine combined with standard chelation therapy will be assessed at baseline and 12 months posttreatment by both cardiac t2\*mri, and cardiac function. the recruitment period is projected to be 12 months from initiation.


Eligibility criteria:
participant inclusion criteria participants who meet all of the following criteria will qualify for entry into the study: 1. diagnosis of transfusion-dependent thalassemia being followed at the rbc clinic at tgh 2. age 18 or older 3. on a stable dose of iron chelation for \>30 days. combination iron chelation regimen is allowed in the study 4. cardiac mri t2\* ≥8ms measured within 3 months prior to randomization. 5. preserved left ventricular ejection fraction (lvef) \>50% as measured by cardiac mri measured within 3 months prior to randomization. participant exclusion criteria participants who meet any of the following criteria will be excluded from the study: 1. more than 16 transfusions in the past 12 months or those who are anticipated to be on a 3 week transfusion schedule during the study period 2. serum ferritin \< 500 ng/ml at screening 3. liver iron concentration \> 40 mg/g dw as measured by liver r2 mri (ferriscan) measured within 3 months prior to randomization 4. signs and symptoms consistent with congestive heart failure in the opinion of the investigator 5. as a result of medical review, physical examination or screening investigations, the investigator considers the subject unfit for the study. 6. no fixed address 7. interval advent of general contraindications to mri. 8. taking another investigational product within 30 days of anticipated date of randomization 9. women who are currently pregnant or plan to become pregnant during the study period
efficacy of baclofen in the treatment of alcohol addiction

Conditions: Liver Cirrhosis, Alcoholic

Summary: intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. however no trials have evaluated the efficacy of anti-craving drugs in these patients because of the concern that these medications might worsen liver disease. baclofen is effective to reduce alcohol craving improving abstinence in alcohol-dependent patients. it is mainly eliminated by kidney. no hepatic side-effects have been reported in treated patients. the present study investigates the efficacy and safety of baclofen in achieving and maintaining abstinence in alcoholic cirrhotic patients.


Eligibility criteria:
inclusion criteria: * age ranging from 18 to 75 years * diagnosis of alcohol dependence according to dsm iv criteria * diagnosis of liver cirrhosis * alcohol intake of at least 2 heavy drinking days (men \> 5 drinks/days; women \> 4 drinks/day) per week, on average and an average overall consumption of 21 drinks/week or more for men and 14 drinks/week or more for women during the 4 weeks prior to enrolment * presence of a referred family member exclusion criteria: * severe heart or lung disease * kidney alterations and/or hepato-renal syndrome * tumours, including hepatocellular carcinoma * metabolic diseases, including diabetes * clinical signs of hepatic encephalopathy * patients treated with interferon or corticosteroids within the last 60 days * psychopathological illness undergoing treatment with psychoactive drugs * epilepsy or epileptiform convulsions * addiction to drugs other than nicotine

Keywords: liver cirrhosis alcoholism craving
the diabetic retinopathy screening, prevention and control program

Conditions: Diabetic Retinopathy

Summary: the greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(dr), leading to extremely high rates of disability and blindness. early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with dr. however, compared with the high prevalence of diabetes in china, the dr screening ability is relatively inadequate. to change this situation, deep learning(dl), a form of artificial intelligence (ai), might be a potential effective method to solve this dilemma.

the greatest harm of diabetes is various acute and chronic complications, especially dr, leading to extremely high rates of disability and blindness. however, if the fundus examination is carried out regularly in the early stages of onset, the risk of blindness can be significantly reduced. therefore, early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with dr. however, compared with the high prevalence of diabetes in china, the dr screening ability is relatively inadequate. the diabetic retinopathy screening and prevention program is a branch project of mmc. its purpose is to carry out an efficient workflow for early detecting, timely managing of dr, and to establish a referral system for implementing treatment and the long-term follow-up of dr by means of dl. first, in order to improve its sensitivity and specificity, more participants are involved in other medical institutes besides mmcs, then we can effectively explore the prevalance of dr in china and helps to early screening, prevention, treatment and referal process of dr. secend, we collect participants' serum, plasma,dna, several medical stastistics and life styles to explore genetics, new biomarkers, risk factors of dr. objective: 1. to validate the methodology and feasibility of dr screening using a dl based automated dr grading system in clinical practice. 2. to explore the prevalence of dr and subgroup identification, and fundus images analysis, etc. 3. to explore the genetics, new biomarkers, risk factors of dr. 4. to explore the methods of early screening, prevention, treatment and referal process of dr.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for type 2 diabetes according to the world health organization (who) in 1999; type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, cushing's syndrome, thyroid dysfunction, or acromegaly; * subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study. exclusion criteria: * those who have a history of drug abuse; * sexually transmitted diseases such as aids and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase; * any condition that the investigator think that the subject is not suitable for participating in the study. for detailed in-/ex-clusion criteria please see the study protocol.
efficacy and safety study of abt-288 in subjects with mild-to-moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: efficacy and safety study of abt-288 in adults with mild-to-moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: 1. have voluntarily signed an informed consent. 2. subject meets diagnostic criteria criteria for probable ad (alzheimer's disease). 3. female subjects must be postmenopausal for at least 2 years or surgically sterile. 4. male subjects must be surgically sterile, sexually inactive or using a barrier method of birth control. 5. subject has an identified, reliable caregiver. 6. subject has a ct or mri scan within 36 months prior to randomization. 7. with the exception of a diagnosis of mild-to-moderate ad and the presence of stable medical conditions, the subject is generally in good health based on medical history, physical examination, vital signs, clinical lab tests and ecg exclusion criteria: 1. subject is currently taking or has taken a medication for the treatment of ad or dementia with 60 days of screening visit, or is participating in cognitive therapy for the treatment of ad or dementia. 2. subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence. 3. subject has a history of any significant neurologic disease other than ad. 4. subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation. 5. subject has received any investigation product within 6 weeks prior to study drug administration.
lyon uveitis study

Conditions: Uveitis

Summary: uveitis or inflammation of the uveal tract results from a heterogeneous collection of disorders of varying etiologies and pathogenic mechanisms. uveitis is relatively frequent in industrial countries with an estimation of 115 cases for 100 000 persons and is associated with a blindness risk of 10%. causes of uveitis can be related to different etiologies (infectious, inflammatory or general inflammatory diseases). therapeutic care is based on ophthalmologic and systemic diagnosis and treatment strategy depends on the severity of inflammation. the main objective of the lyon uveitis study is to analyze the uveitis ophthalmologic etiology and diagnostic and therapeutic care of the patients. this study is proposed to all patients diagnosed for uveitis and referred to the department of internal medicine of the croix rousse hospital, lyon, france for etiologic diagnosis or treatment. analysis of i) patients' characteristics, ii) the relevance of complementary exams to determine the uveitis etiology, iii) treatment used. this study will allow a better characterization of the disease on diagnosis practices and therapeutic care.


Eligibility criteria:
inclusion criteria: * diagnosis of uveitis * first consultation in the department of internal medicine at the croix-rousse hospital, lyon, france exclusion criteria: -